At the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Janelle Hart
Advertisement
Articles by Janelle Hart
Efficacy of adjuvant mitotane for patients with adrenocortical carcinoma following surgery was presented at 2022 ASCO GU.
Data reported from the phase 3 SPOTLIGHT trial of the novel theranostic 18F-rhPSMA-7.3 at 2022 ASCO GU show “excellent image quality” for prostate cancer recurrence detection, according to expert.
Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
2
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
3
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
4
Matched donor allogeneic CAR T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion
5
